Caterina Messina
Bergamo, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Total and Regional Changes in Body Composition in Metastatic Hormone-sensitive Prostate Cancer Patients Randomized to Receive Androgen Deprivation + Enzalutamide ± Zoledronic Acid. The BONENZA Study.
Journal: European urology oncology
Published: December 16, 2024
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.
Journal: Prostate cancer and prostatic diseases
Published: November 17, 2024
Whole-body Diffusion-weighted Magnetic Resonance Imaging for Assessment of the Bone Response Rate in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Enzalutamide.
Journal: European urology
Published: March 10, 2024
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 21, 2021
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic.
Journal: The oncologist
Published: July 03, 2020
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Journal: Future oncology (London, England)
Published: September 13, 2018
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
Journal: Oncotarget
Published: February 28, 2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Journal: Future oncology (London, England)
Published: January 19, 2016
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Journal: Medicine
Published: January 15, 2016
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Journal: Future oncology (London, England)
Published: October 06, 2015
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Journal: Clinical genitourinary cancer
Published: May 27, 2015
Last Updated: 09/26/2026